FMP
Cyteir Therapeutics, Inc.
CYT
NASDAQ
Inactive Equity
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
3.02 USD
-0.07 (-2.32%)
About
ceo
Dr. Markus F. Renschler M.D.
sector
Healthcare
industry
Biotechnology
website
https://cyteir.com
exchange
NASDAQ
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
CIK
0001662244
ISIN
US23284P1030
CUSIP
550241103
Address
128 Spring Street
Phone
857 285 4140
Country
US
Employee
46
IPO Date
Jun 18, 2021
Summary
CIK
0001662244
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
550241103
ISIN
US23284P1030
Country
US
Price
3.02
Beta
0.1
Volume Avg.
167.62k
Market Cap
108.71M
Shares
-
52-Week
1.65-3.19
DCF
4.15
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.25
P/B
-
Website
https://cyteir.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CYT News
It looks like there's no news available.
